WVP
AQST icon

Worth Venture Partners’s Aquestive Therapeutics AQST Stock Holding History

Worth Venture Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-94,500
Closed -$550K – 106
2019
Q4 		$550K Buy
+94,500
New +$492K 0.27% 49

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Worth Venture Partners's AQST Position: Q1 2020 in Review

Worth Venture Partners sold out of Aquestive Therapeutics (AQST) in Q1 2020, closing a stake of 94,500 shares — an estimated $550K sold.

Worth Venture Partners first reported a position in AQST in Q4 2019 and held it in 1 quarter. The position peaked at $550K in Q4 2019. 42 funds tracked by Wall St. Rank hold AQST as of Q1 2020.

  • Worth Venture Partners reported no remaining Aquestive Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Worth Venture Partners sold 94,500 Aquestive Therapeutics shares in Q1 2020, an estimated $550K.
  • Worth Venture Partners first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 1 quarter.
  • Worth Venture Partners's Aquestive Therapeutics position peaked at $550K in Q4 2019.
  • 42 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2020.

Based on Worth Venture Partners's 13F filing for Q1 2020, filed 15 May 2020.